Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal(Stanford Medicine), John Bridgewater(University College London Hospitals NHS Foundation Trust), Karim A. Benhadji(Dana-Farber Cancer Institute), Volker Wacheck(Taiho Oncology (United States)), Robert S. Epstein(Dana-Farber Cancer Institute), Markus Moehler(Johannes Gutenberg University Mainz), Josep Tabernero(Deaconess Hospital), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Thomas B. Karasic(Hospital of the University of Pennsylvania), Philippe A. Cassier(Centre Léon Bérard), Tehseen Salimi(Dana-Farber Cancer Institute), Thomas A. Abrams(Dana-Farber Cancer Institute), Heinz‐Josef Klümpen(University Medical Center Groningen), Yoshito Komatsu(Hokkaido University Hospital), Junji Furuse(Kanagawa Prefectural Hospital Organization), Do‐Youn Oh(Seoul National University Hospital), Yao Fu(Illumina (United States)), Daniel H. Ahn(Mayo Clinic Hospital), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Juan W. Valle(Cancer Research UK Manchester Institute), Edith P. Mitchell(Thomas Jefferson University Hospital), Antoine Hollebecque(Institut Gustave Roussy), Mei Liu(Dana-Farber Cancer Institute), Abdel‐Baset Halim(Institut Gustave Roussy), Kunihiro Masuda(Tohoku University), Li‐Tzong Chen(Kaohsiung Medical University), Yaohua He(Dana-Farber Cancer Institute), Amit Mahipal(Dana-Farber Cancer Institute), Heung-Moon Chang(Ulsan College), Chigusa Morizane(Tokyo National Hospital)
New England Journal of Medicine
January 18, 2023
Cited by 530


Related Papers